Loading
A phase 1/2 trial of IMP9064 in advanced solid tumours, run by Impact Therapeutics, Inc., now recruiting.
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05269316 by Impact Therapeutics, Inc., with 61 participants planned, started 2022-02-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: IMP9064.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IMPACT Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IMPACT Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares IMPACT Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/